| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 9.44 | 0.13 (+1.45%) | 5.65 - 11.34 | 554.2 thousand (Below Avg) |
Market data as of 3:23PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 9.30 |
|---|---|
| Previous Close | 9.31 |
| Day's Range | 9.11 - 9.50 |
| Market Cap | 1.1B |
| Avg Volume (10 Day) | 1.4M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -1.62 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013
Business Wire - Tuesday 05/21/2013 9:25 AM ET
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
PR Newswire - Thursday 05/16/2013 6:02 PM ET
Nektar Therapeutics Reports Financial Results for the First Quarter of 2013
PR Newswire - Thursday 05/09/2013 4:15 PM ET
Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets
PR Newswire - Thursday 05/02/2013 5:00 PM ET
| NKTR | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 10.39% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 12.46 |
| Company | Last | Change |
|---|---|---|
| ACADIA Pharmaceuticals Inc | 14.29 | +3.63% |
| Puma Biotechnology Inc | 38.81 | +0.67% |
| Synageva Biopharma Corp | 40.89 | +0.73% |
| Lexicon Pharmaceuticals Inc | 2.19 | 0.00% |
| TESARO Inc | 34.01 | -2.83% |
Data is delayed by at least 15 min.